Diazepam and buspirone alter neuropeptide Y-like immunoreactivity in rat brain

Neuropeptides

Volumn 33, Issue 6, 1999, Pages 542-549

  Krysiak, R ^a   Obuchowicz, E ^a   Herman, Z S ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

BUSPIRONE; DIAZEPAM; NEUROPEPTIDE Y DERIVATIVE;

AMYGDALOID NUCLEUS; ANIMAL EXPERIMENT; ARTICLE; BRAIN; CONTROLLED STUDY; DRUG EFFECT; FRONTAL CORTEX; HYPOTHALAMUS; IMMUNOREACTIVITY; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RAT;

EID: 0033369843     PISSN: 01434179     EISSN: None     Source Type: Journal    
DOI: 10.1054/npep.1999.0776     Document Type: Article

References (52)

1. Heilig M., Widerlöv E. Neurobiology and clinical aspects of neuropeptide Y. Crit Rev Neurobiol. 9:1995;115-136.
2. Blomqvist A. G., Herzog H. Y-receptor subtypes-how many more? Trends Neurosci. 20:1997;294-298.
3. Heilig M. Antisense inhibition of neuropeptide Y (NPY)-Y1 receptor expression blocks the anxiolytic-like action of NPY in amygdala and paradoxically increases feeding. Regul Pept. 59:1995;201-205.
4. Heilig M., Söderpalm B., Engel J. A., Widerlöv E. Centrally administered neuropeptide Y (NPY) produces anxiolytic-like effects in animal anxiety models. Psychopharmacology. 98:1989;524-529.
5. Heilig M., McLeod S., Brot M. Anxiolytic-like action of neuropeptide Y: mediation by Y1 receptors in amygdala, and dissociation from food intake effects. Neuropsychopharmacology. 8:1993;357-363.
6. Broqua P., Wettstein J. G., Rocher M. N., Gauthier-Martin B., Junien J. L. Behavioral effects of neuropeptide Y receptor agonists in the elevated plus-maze and fear-potentiated startle procedures. Behav Pharmacol. 6:1995;215-222.
7. 34] neuropeptide Y on experimental gastric lesion formation and gastric secretion in the rat. J Pharmacol Exp Ther. 266:1993;339-343.
8. Junien J. L., Gue M., Bueno L. Neuropeptide Y and sigma ligand (JO 1784) act through a Gi protein to block the psychological stress and corticotropin-releasing factor-induced colonic motor activation in rats. Neuropharmacology. 30:1991;1119-1124.
9. Britton K. T., Southerland S., Van Uden E., Kirby D., Rivier J., Koob G. Anxiolytic activity of NPY receptor agonists in the conflict test. Psychopharmacology. 132:1997;6-13.
10. 1receptor antagonist BIBP 3226: antagonism with diazepam. Eur J Pharmacol. 317:1996;R3-R4.
11. 1receptor antagonist BIBP 3226 administered into the dorsal periaqueductal gray matter in rats. Regul Pept. 75-76:1998;255-262.
12. Kask A., Rago L., Harro J. Anxiolytic-like effect of neuropeptide Y (NPY) and NPY 13-36 microinjected into vicinity of locus coeruleus in rats. Brain Res. 788:1998;345-348.
13. Nakajima M., Inui A., Asakawa A. Neuropeptide Y produces anxiety via Y2-type receptors. Peptides. 19:1998;359-363.
14. König J. F. R., Klippel R. A. The rat brain. A stereotaxic atlas of the forebrain and lower parts of the brain stem. 1963.
15. Aoki C., Pickel V. M. Neuropeptide Y in the cerebral cortex and the caudate-putamen nuclei: ultrastructural basis for interactions with GABAergic and non-GABAergic neurons. J Neurosci. 9:1989;4333-4354.
16. Horvath T. L., Bechmann I., Naftolin F., Kalra S. P., Leranth C. Heterogeneity in the neuropeptide Y-containing neurons of the rat arcuate nucleus: GABAergic and non-GABAergic subpopulations. Brain Res. 756:1997;283-286.
17. Mc Donald A., Pearson J. C. Coexistence of GABA and peptide immunoreactivity in non-pyramidal neurons of the basolateral amygdala. Neurosci Lett. 100:1989;53-58.
18. Massari V. J., Chan J., Chronwall B. M., O'Donohue T. L., Oertel W. H., Pickel V. M. Neuropeptide Y in the rat nucleus accumbens: ultrastructural localization in aspiny neurons receiving synaptic input from GABAergic terminals. J Neurosci Res. 19:1988;171-186.
19. Chang C. L., Tsai Y. C., Lin S. S., Cheng J. T. Effect of premedication on the changes of neuropeptide Y (NPY) in anesthesia. Acta Anaesthesiol Sin. 30:1992;147-152.
20. Ehlers C. L., Somes C., Lopez A., Kirby D., Rivier J. E. Electrophysiological actions of neuropeptide Y and its analogs: new measures for anxiolytic therapy? Neuropsychopharmacology. 17:1997;34-43.
21. Heilig M., Wahlestedt C., Widerlöv E. Neuropeptide Y (NPY)-induced suppression of activity in the rat: evidence for NPY receptor heterogenity and for interaction with α-adrenoceptors. Eur J Pharmaco. 157:1988;205-213.
22. Sperk G., Herzog H. Anticonvulsant action of neuropeptide Y. Nature Med. 3:1997;228-229.
23. Yamada K., Shibasaki T., Tsumori C. Neuropeptide Y reverses corticotropin-releasing hormone- and psychological stress-caused shortening of sodium pentobarbital-induced sleep in rats. Brain Res. 725:1996;272-275.
24. Everitt B. J., Hökfelt T. The coexistence of neuropeptide Y with other peptides and amines in the central nervous system. Mutt V., Hökfeld T., Fuxe K., Lundberg J. M. Neuropeptide Y. 1989;61-72 Raven Press, New York.
25. Kakigi T., Maeda K. Effect of serotonergic agents on regional concentrations of somatostatin and neuropeptide Y-like immunoreactivities in rat brain. Brain Res. 599:1992;45-50.
26. Bendotti C., Tarizzo G., Fumagalli F., Baldessari S., Samanin R. Increased expression of preproneuropeptide Y and preprosomatostatin mRNA in striatum after selective serotoninergic lesions in rats. Neurosci Lett. 160:1993;197-200.
27. Midgley L. P., Bush L. G., Gibb J. W., Hanson G. R. Differential regulation of neuropeptide Y systems in limbic structures of the rat. J Pharmacol Exp Ther. 267:1993;707-713.
28. Davis M., Rainnie D., Cassell M. Neurotransmission in the rat amygdala related to fear and anxiety. Trends Neurosci. 17:1994;208-214.
29. Zangrossi H. Jr, Graeff F. G. Behavioral effects of intra-amygdala injections of GABA and 5-HT acting drugs in the elevated plus-maze. Brazilian J Med Biol Res. 27:1994;2453-2456.
30. 1Areceptor agonists 8-OH-DPAT, ipsapirone and buspirone in the rat. Eur J Pharmacol. 249:1993;341-351.
31. Treit D. Evidence that tolerance develops to the anxiolytic effect of diazepam in rats. Pharmacol Biochem Behav. 22:1985;383-387.
32. Harro J., Lang A., Vasar E. Long-term diazepam treatment produces changes in cholecystokinin receptor binding in rat brain. Eur J Pharmacol. 180:1990;77-83.
33. Westenberg H. G. M., den Boer J. A. The neuropharmacology of anxiety: a review on the role of serotonin. den Boer J. A., Ad Sitsen J. M. Handbook of Depression and Anxiety: A Biological Approach. 1994;405-446 Marcel Dekker Inc. New York.
34. Zacharko R. M., Koszycki D., Mendella P. D., Bradwejn J. Behavioral, neurochemical, anatomical and electrophysiological correlates of panic disorder: multiple transmitter interaction and neuropeptide colocalization. Prog Neurobiol. 47:1995;371-423.
35. Plaznik A., Stefanski R., Palejko W., Kostowski W. Serotonergic mechanisms in the nucleus accumbens affected by chronic desipramine treatment. Pharmacol Biochem Behav. 39:1991;43-48.
36. McNamara R. K., Skelton R. W. Tolerance develops to the spatial learning deficit produced by diazepam in rats. Pharmacol Biochem Behav. 56:1997;383-389.
37. Cohen R. S., Carlin R. K., Grab D. J., Siekewitz P. Phosphoproteins in postsynaptic densities. Prog Brain Res. 56:1982;49-76.
38. Algeri S., De Luigi A., De Simoni M. G. Multiple and complex effects of buspirone on central dopaminergic system. Pharmacol Biochem Behav. 29:1988;823-826.
39. Obuchowicz E., Turchan J. Effects of acute or long-term treatment with chlorpromazine, haloperidol or sulpiride on NPY-LI concentrations in the nucleus accumbens of rat. Eur Neuropsychopharmacol. 9:1999;51-59.
40. Shekhar A., Hingtgen J. N., DiMicco J. A. GABA receptors in the posterior hypothalamus regulate experimental anxiety in rats. Brain Res. 512:1990;81-88.
41. Dryden S., Wang Q., Frankish H. M., Pickavance L., Williams G. The serotonin (5-HT) antagonist methysergide increases neuropeptide Y (NPY) synthesis and secretion in the hypothalamus of the rat. Brain Res. 699:1995;12-18.
42. Dryden S., Frankish H. M., Wang Q., Williams G. Increased feeding and neuropeptide Y (NPY) but not NPY mRNA levels in the hypothalamus of the rat following central administration of the serotonin synthesis inhibitor p -chlorophenylalanine. Brain Res. 724:1996;232-237.
43. 1Aagonist flesinoxan on hypothalamic neuropeptide Y in the rat: evidence that NPY may mediate serotonin's effects on food intake. Peptides. 17:1996;943-949.
44. Li E. T., Luo S. Buspirone-induced carbohydrate feeding is not influenced by route of administration and nutritional status. Brain Res Bull. 30:1993;547-550.
45. Calogero A. E., Kamilaris T. C., Bernardini R., Johnson E. O., Chrousos G. P., Gold P. W. Effects of peripheral benzodiazepine receptor ligands on hypothalamic-pituitary-adrenal axis function in the rat. J Pharmacol Exp Ther. 253:1990;729-737.
46. 1Areceptor subtype in the paraventricular nuclei of the hypothalamus induces CRH and ACTH release in the rat. Neuroendocrinology. 56:1992;797-802.
47. Krysiak R., Obuchowicz E., Herman Z. S. Interactions between the neuropeptide Y system and the hypothalamic-pituitary-adrenal axis. Eur J Endocrinol. 140:1999;130-136.
48. Areceptor stimulation in mouse brain. Mol Brain Res. 13:1992;277-281.
49. Martin J. B., Beal M. F., Kowall N., Mazurek M. Alterations in neuropeptide Y in neurological disorders. Mutt V., Hökfelt T., Fuxe K., Lundberg J. M. Neuropeptide Y. 1989;313-320 Raven Press, New York.
50. S mialowska M., Gastol-Lewinska L., Tokarski K. The role of α-1 adrenergic receptors in the stimulating effect of neuropeptide Y (NPY) on rat behavioural activity. Neuropeptides. 26:1994;225-232.
51. Flood J. F., Hernandez E. N., Morley J. E. Modulation of memory processing by neuropeptide Y. Brain Res. 421:1987;280-290.
52. 2A/2Creceptor binding sites in the rat cerebral cortex. Brain Res. 795:1998;264-276.